Jubilant to invest $92 million toward manufacturing sterile injectables

Jubilant HollisterStier, a contract development and manufacturing organization (CDMO) and wholly owned subsidiary of parent company Jubilant Pharmova Limited, will be investing $92 million toward increasing sterile injectable manufacturing capacity at its site in Spokane, WA. Specifically, the funds will go toward setting up a high-speed 400-vials-a-minute injectable fill line with isolator technology, which is projected to boost the Spokane facility’s capacity by 50%.

This expansion, spread over 50,000 square feet, will also consist of two 300 square-foot lyophilizers. The investment’s end products are expected to be commercially operational by the end of 2024.

“We are pleased to announce the planned expansion of the sterile injectable manufacturing capacity at this critical juncture. With two facilities in North America working to manufacture multiple Covid-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic and are prepared for a potential future pandemic response,” says Pramod Yadav, CEO of Jubilant Pharma Limited. “This expansion will also help us meet high demand from our global specialty pharmaceutical customers, with whom the company has established strong relationships.”